Soniko Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.95 M
- Company Age 40 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.50 M
- Revenue Growth 28.18%
- Profit Growth 83.97%
- Ebitda 115.47%
- Net Worth -1.74%
- Total Assets 5.87%
About Soniko Pharmaceuticals
Soniko Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 13 November 1984 and has a history of 40 years and three months. Its registered office is in Agra, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.95 M.
The company currently has active open charges totaling ₹2.50 M.
Manjeet Singh and Darshan Singh serve as directors at the Company.
Company Details
-
Location
Agra, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U85110UP1984PTC006823
-
Company No.
006823
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
13 Nov 1984
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Soniko Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manjeet Singh
|
Director | 13-Nov-1984 | Current |
|
Darshan Singh
|
Director | 13-Nov-1984 | Current |
Financial Performance of Soniko Pharmaceuticals.
Soniko Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 28.18% increase. The company also saw a substantial improvement in profitability, with a 83.97% increase in profit. The company's net worth dipped by a decrease of 1.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Soniko Pharmaceuticals?
In 2020, Soniko Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹2.50 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of Bikaner & Jaipur : 0.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 07 Oct 1997 | State Bank Of Bikaner & Jaipur | ₹2.50 M | Open |
How Many Employees Work at Soniko Pharmaceuticals?
Unlock and access historical data on people associated with Soniko Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Soniko Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Soniko Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
